Advances and applications of induced pluripotent stem cells

Direct reprogramming of somatic cells into pluripotent cells is an emerging technology for creating patient-specific cells, and potentially opens new scenarios in medical and pharmacological fields. From the discovery of Shinya Yamanaka, who first obtained pluripotent cells from fibroblasts by retro...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of physiology and pharmacology 2012-03, Vol.90 (3), p.317-325
Main Authors: Pietronave, Stefano, Prat, Maria
Format: Article
Language:English
Subjects:
Adenoviridae - genetics
Animals
drug discovery
découverte de médicaments
Fibroblasts
Gene expression
Genomics
Health aspects
Humans
Induced Pluripotent Stem Cells - physiology
Induced Pluripotent Stem Cells - transplantation
iPS
MicroRNAs - genetics
médecine régénérative
Pharmacology
Physiological aspects
Plasmids
Proteins
regenerative medicine
retrovirus
rétrovirus
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct reprogramming of somatic cells into pluripotent cells is an emerging technology for creating patient-specific cells, and potentially opens new scenarios in medical and pharmacological fields. From the discovery of Shinya Yamanaka, who first obtained pluripotent cells from fibroblasts by retrovirus-derived ectopic expression of defined embryonic transcription factors, new methods have been developed to generate safe induced pluripotent stem (iPS) cells without genomic manipulations. This review will focus on the recent advances in iPS technology and their application in pharmacology and medicine.
ISSN:0008-4212
1205-7541
DOI:10.1139/y11-125